Regulatory T cell suppressive pathway (Treg suppressive pathway)

The Regulatory T cell (Treg) suppressive pathway encompasses the diverse molecular and cellular mechanisms by which Tregs inhibit immune responses to maintain self-tolerance and immune homeostasis (Sakaguchi et al., 2008, Cell). Tregs, typically defined by the expression of the transcription factor FOXP3 and high levels of CD25, utilize several distinct modes of suppression, including the secretion of inhibitory cytokines like IL-10 and TGF-beta, direct cytolysis of effector cells, and metabolic disruption through the production of adenosine via CD39 and CD73 (Vignali et al., 2008, Nature Reviews Immunology). Additionally, Tregs express high levels of inhibitory receptors such as CTLA-4, which downregulates the co-stimulatory capacity of antigen-presenting cells (Togashi et al., 2019, Nature Reviews Clinical Oncology). In cancer, the recruitment and expansion of Tregs within the tumor microenvironment represent a major mechanism of immune evasion, shielding the tumor from cytotoxic T cell attack (Ohue & Nishikawa, 2019, Cancer Science). Conversely, a deficiency or dysfunction in the Treg suppressive pathway is a primary driver of autoimmune diseases and chronic inflammation (Plitas & Rudensky, 2016, Cancer Immunology Research). Therapeutic interventions targeting this pathway include immune checkpoint inhibitors that deplete or inhibit Tregs in oncology, as well as low-dose IL-2 or Treg-cell therapies designed to bolster suppressive function in autoimmune and transplant settings (Togashi et al., 2019, Nature Reviews Clinical Oncology).

Other names

Treg suppression mechanismRegulatory T cell pathwayImmunosuppressive Treg networkFOXP3-mediated suppressive pathway

Modulation of Treg activity through depletion, inhibition of suppressive receptors (e.g., CTLA-4), or metabolic interference (e.g., IDO inhibition) to enhance anti-tumor immunity, or expansion of Tregs to treat autoimmunity.